stockportfolio.pro
Stocks / ESTA vs RARE
ESTA vs RARE
Establishment Labs Holdings Inc. and Ultragenyx Pharmaceutical Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Establishment Labs Holdings Inc. (ESTA) | Ultragenyx Pharmaceutical Inc. (RARE) | |
|---|---|---|
| Market cap | $2.4B | $2.3B |
| Revenue (latest FY) | $211.08M | $673.00M |
| Net income (latest FY) | $-51.06M | $-575.00M |
| Revenue growth (5y CAGR) | 20.0% | 19.9% |
| Net margin | -24.2% | -85.4% |
| Return on equity | -216.9% | 718.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ESTA — free Open RARE — freeFrequently asked questions
Which is bigger, ESTA or RARE?
Establishment Labs Holdings Inc. is larger by market capitalization — $2.4B versus $2.3B.
Which grows faster, ESTA or RARE?
Over the last five fiscal years, Establishment Labs Holdings Inc. grew revenue faster — 20.0%/yr versus 19.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.